MicroRNAs in Psoriasis|
The authors present a comprehensive review of what is known about microRNAs and their role in the pathogenesis of psoriasis. [J Invest Dermatol] Abstract
Visit our reviews page to see a complete list of reviews in the dermal cell research field.
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis|
Valeant Pharmaceuticals International, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application submitted by AstraZeneca in partnership with Valeant, for brodalumab injection, a monoclonal antibody that targets the IL-17 receptor, in development for patients with moderate-to-severe plaque psoriasis. [Valeant Pharmaceuticals International, Inc.] Press Release
Rockland Immunochemicals, Inc. Introduces Melanoma Cell Lines in Collaboration with The Wistar Institute
Rockland Immunochemicals, Inc. announced the availability of a new collection of human melanoma cell lines that have been developed and characterized over several decades in the laboratory of Meenhard Herlyn, D.V.M., D.Sc., Caspar Wistar Professor in Melanoma Research, Director of the Melanoma Research Center, and professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia. [Rockland Immunochemicals, Inc.] Press Release
DDK 60 Million Awarded for Four Interdisciplinary Research Projects
The Novo Nordisk Foundation has awarded grants for four interdisciplinary research projects under the Interdisciplinary Synergy Program. Each project receives up to DKK 15 million per year for three years. [Novo Nordisk Foundation] Press Release
From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols. Watch the video.